Sign in

NCT05784415Completed

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

Observational Cohort Study of People Living With HIV Treated With CD19-directed CAR T Cell Therapy for B-cell Lymphoid Malignancies

Source: ClinicalTrials.gov · Last updated 28 Oct 2026

Brief summary (registry, in English)

This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 30, 2023. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data

Status (registry)
Completed
Study type
Observational
Enrollment
35 (actual)
First submitted
13 Mar 2023
Start date
22 May 2021
Primary completion date
14 Nov 2024
Lead sponsor
AIDS Malignancy Consortium
NCT number
NCT05784415

What you commit to

  • Study type: Observational
  • Participants enrolled: 35
  • From 22 May 2021 to the primary completion date, 14 Nov 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior treatment with any CAR T cell therapy

Who the study is looking for

  • Documented history of HIV infection
  • Received CD19-directed CAR T cell therapy for acute lymphoblastic leukemia, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, or primary mediastinal B-cell lymphoma
  • Age ≥ 18 years

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pennsylvania Hospital
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.